Leadership & Pay ·
Metagenomi Therapeutics elects Juergen Eckhardt and Eric Bjerkholt as Class II Directors; Brian Thomas resigns from the Board
MGXMetagenomi Therapeutics, Inc.
On June 9, 2026, Brian C. Thomas, Ph.D. resigned from the Board of Directors of Metagenomi Therapeutics, Inc. Dr. Thomas's resignation was not due to any disagreement with the company's operations, policies, or practices. Additionally, the company's 2026 annual meeting of stockholders, held virtually, resulted in the following election of Class II Directors, Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A., to serve until 2029. Metagenomi Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.